MedTrace Logo

Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome

NCT00858689 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-02-18

Study results available
· View outcomes & findings →

Summary

Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment, developmental disability and autism. Minocycline is an antibiotic that has recently been used to treat the mouse model for Fragile X, and was found to reverse the structural abnormalities that are seen their brain cells. The purpose of this research study is to determine if minocycline is an effective treatment for patients with fragile X syndrome (FXS).

Conditions

  • Fragile X Syndrome

Interventions

DRUG

Minocycline

50-100 mg PO BID for 8 weeks with an option for a 1 year extension.

Sponsors & Collaborators

  • Fragile X Research Foundation of Canada

    collaborator OTHER

  • FRAXA Research Foundation

    lead OTHER

Principal Investigators

  • Carlo Paribello, M.D. · Fragile X Research Foundation of Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-11-30
Completion
2009-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00858689 on ClinicalTrials.gov